Amedisys (AMED) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amedisys Reports Fourth Quarter and Year End 2021 Financial Results; Issues 2022 Guidance
February 23, 2022 4:05 PM ESTBATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2021.
Three-Month Periods Ended December 31, 2021 and 2020
Net service revenue increased $8.6Â million to $559.3Â million compared to $550.7Â million in 2020.Net income attributable to Amedisys, Inc. of $34.0Â million compared to $45.2Â million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.36 in 2020.Adjusted Quarterly Results*
Adjusted EBITDA of $64.8Â million compared to $78.1Â million in 2020.Adjusted net service revenue of $559.3Â million compared to $550.7Â million in... More